37 DCVMN members each supplied from 50k to 1.5B doses in 2018/2019 (according to a survey), totaling at approximately 3.5 billion doses in this timeframe. There is potential to increase the manufacturing capacity to accommodate a higher demand if these members go beyond typical parameters such as the filling capacity of single-dose syringes and routine Monday-Friday operations. Additionally, the approximations of doses did not include unreleased or bulk in-stock doses, and 4 members were not counted in the survey. Some vaccines included in the count were monovalent.

DCVMN past supply history

It will cost an estimated $50 million for vaccine manufacturing companies, equipped with personal and infrastructure, to manufacture hundreds of millions of doses of a single vaccine, according to Gavi (the Vaccine Alliance). For new companies, this estimation surges to approximately $700 million.

Projected Cost

- DCVMN past supply history
- projected cost 

Stanford University

Compilation of 2019 data, online research about COVID-19 vaccine activity by DCVMN organizations, and supply capacity surveys were used to analyze the potential of DCVMN member organizations in the following areas:
- Research, Development, and Technology
- Scaling
- Fill-finish and distribution
- Supply of other vaccines

Methods of Analysis of DCVMN

Pagliusi, S., Jarrett, S., Hayman, B., Kreysa, U., Prasad, S. D., Reers, M., Hong Thai, P., Wu, K., Zhang, Y. T., Baek, Y. O., Kumar, A., Evtushenko, A., Jadhav, S., Meng, W., Dat, D. T., Huang, W., & Desai, S. (2020). Emerging manufacturers engagements in the COVID -19 vaccine research, development and supply. Vaccine, 38(34), 5418–5423. https://doi.org/10.1016/j.vaccine.2020.06.022

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7287474/

Emerging manufacturers engagements in the COVID −19 vaccine research, development and supply


19 DCVMN members involved in R&D for 22 potential vaccines. Out of these, 4 members’ are executing Phase 1 or ½ of clinical trials, and the remaining vaccines were in the preclinical phase in May 2020.

DCVMN Research, Development, and Technology

Factors for Scaling

Filling and finishing is the final stage in the process of vaccine manufacturing and also the most vulnerable to experiencing congestion in production. There are a number of possible solutions for this issue:
-Facilities producing influenza vaccine are likely to have excess capacity for manufacturing
-Adding shifts 
-Companies with a lot of staff and resources are leading the way in building the filling capacity for COVID vaccines
-14 DCVMN members with excess capacity and resources have expressed their capabilities and willingness to tackle surge manufacturing or filling. - --Many members have available resources for formulation and fill-finish.
-Fixing holes in the supply chain



Fill-finish and distribution

About 50 different vaccines for conditions other than COVID-19 are produced or distributed by members of the DCVMN.

Learn Before

Related

Learn After